Vanguard Capital Management
APRE icon

Vanguard Capital Management’s Aprea Therapeutics APRE Stock Holding History

Vanguard Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Buy
22,882
+3,260
+17% +$2.72K ﹤0.01% 4016
2026
Q1 		$15K Buy
+19,622
New +$15.4K ﹤0.01% 3999

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's APRE Position: Q2 2026 in Review

Vanguard Capital Management increased its Aprea Therapeutics (APRE) stake by 17% in Q2 2026, buying an estimated $2.72K and bringing the position to 22,882 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

Vanguard Capital Management first reported a position in APRE in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Vanguard Capital Management held 22,882 shares of Aprea Therapeutics worth $18.4K as of Q2 2026.
  • Vanguard Capital Management bought 3,260 Aprea Therapeutics shares in Q2 2026, an estimated $2.72K.
  • Aprea Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4016 holding.
  • Vanguard Capital Management first reported a position in Aprea Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.